Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.

Fusion Pharmaceuticals, a Canada-based cancer treatment spinout of McMaster University, has closed a $105m series B round led by oncology technology provider Varian Medical Systems.
Fight Against Cancer Innovation Trust (Facit), a commercialisation unit backed by Ontario Institute for Cancer Research and the province of Ontario, participated in the round, as did medical group Johnson & Johnson, through its corporate venturing arm Johnson & Johnson Innovation – JJDC.
The round also featured Pivotal BioVenture Partners, the healthcare investment…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?